Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors (STRIDE)
Breast Cancer, Adherence, Medication
About this trial
This is an interventional supportive care trial for Breast Cancer focused on measuring Breast Cancer, Endocrine Therapy, Hormonal Therapy, Symptoms, Distress, Survivors
Eligibility Criteria
Inclusion Criteria:
- Female
- Age 21 or older
- Diagnosis of early-stage (Stage 0-IIIb), hormone receptor + breast cancer
- Within 1 week-36 months of starting adjuvant endocrine therapy
- Ability to read and respond in English
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Currently taking adjuvant endocrine therapy (i.e. if took recent break, has taken within the past 2 weeks)
- Completed primary treatment (i.e., chemotherapy, surgery, and/or radiation) for early-stage breast cancer
- Indicates a score ≥4 on one of the three NCCN adapted distress thermometer study screening questions
Exclusion Criteria:
- Uncontrolled psychosis, active suicidal ideation, or psychiatric hospitalization within the past year
- Cognitive impairment that prohibits participation in the study
- Enrollment in a different clinical trial for breast cancer
- Current participation in formal group psychotherapy or other psychosocial intervention trial
- Undergoing primary treatment for other cancer (i.e., advanced stage cancer)
Sites / Locations
- Massachusetts General Hospital Cancer Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
STRIDE Run-In
STRIDE
Medication Monitoring Control
Stride is delivered as a Five weekly one-hour virtual (videophone) or in-person sessions in small groups with a trained clinician Two 15-minute check-in phone calls later in the study Participants will store hormonal therapy medication in a bottle provided by the study team. Participants will complete questionnaires at enrollment and 3-months post- enrollment
Stride is delivered as six weekly one-hour virtual (videophone) sessions in small groups with a trained clinician (or individually, in the rare instance in which scheduling doesn't allow for groups and the participant is approaching the 12-week assessment window) Two 15-minute check-in phone calls later in the study Participants will store hormonal therapy medication in a bottle provided by the study team. Participants will complete questionnaires at enrollment, 12-weeks, and 24-weeks post-enrollment
Medication monitoring plus standard care Participants will store hormonal therapy medication in a bottle provided by the study team. Participants will complete questionnaires at enrollment, 12-weeks and 24-weeks post-enrollment